Best Forex System Download : Today’s stock pick update

My #1 “rule” for buying options? DON’T

Most Options traders place risky trades, then HOPE for a big payout. But, did you know that 70% of traders get “burned by options?” Jim Fink does things a little differently… he “breaks” the biggest rule in options trading…and walks away with a win- 85% of the time. This unique twist on options trading could hand you an extra $67,548 per year - (Ad)

Get the full details here

Goldman Sachs Just Reported A Monster Earnings Beat

Earnings season day two kicked off with Goldman Sachs delivering a third quarter report that crushed estimates. Goldman reported record earnings of $9.68 per share on $10.78 billion in revenue, compared to analysts’ expectations for earnings per share of $5.57 on revenue of $9.46 billion. The firm’s trading division generated $4.55 billion in revenue, a 29% increase year-over-year, fueled in part by bond trading ...

Read More

Vaxart Inc (NASDAQ: VXRT): Vaxart shares popped yesterday after the clinical-stage biotech announced that the first subject in its Phase 1 study of its oral COVID-19 vaccine candidate, VXA-CoV-1, had been dosed. “We are advancing VXA-CoV2-1 into clinical development based on the strength of pre-clinical data that showed that the vaccine is capable of inducing both a robust system...

Read More

ADM’s fundamentals are improving – its value proposition is not

As is always the case, you have to be careful about casting your net too wide when it comes to industry or sector-based generalizations. A good example is the Technology sector, which has not too surprisingly led the market’s rally from March bear market lows. Many of the biggest names in the sector have led the way, and in particular companies that were positioned on the right side of remote workforce, collaboration, and cloud-based services at the beginning of the year have clearly been a...

Read More

Featured Stock

Novavax, Inc. (NVAX) – Buy Price: $123.00 or better

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company’s lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical t...

Read More